Antibody-drug ConjugatesHER2-low Breast CancerBreast Neoplasms
Investigational drug(s) / intervention(s)
Non-intervention research
Non-intervention research: Non-intervention research
Study summary
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms.
This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative)
* Received sequential administration of two or more ADCs
* Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.
Exclusion Criteria:
* Concomitant with other tumor components at the time of diagnosis;
* Have a history of any other malignant tumors;
* Lack of complete data
Primary outcome measure(s)
Progression-free survival — From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months. The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.